During its first full year on the market, Sanofi’s respiratory syncytial virus antibody Beyfortus easily broke the $1 billion sales threshold. The drug still has plenty of room left to grow in places like the U.S., Sanofi executives said on
read moreAfter repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. Still, questions continue to swirl about an evolving market showdown with Regeneron’s rival drug. More: Vabysmo crosses
read moreThe German manufacturer is ending operations at its Stevenage, U.K., site after a shortfall in demand for cell and gene therapy services prompted the firm to focus more on biologics. More: CDMO Rentschler winds down operations at UK cell and
read moreU.K.-based CDMO Upperton Pharma Solutions expanded its production footprint with the completion of a new £7 million ($8.1 million) sterile manufacturing facility at its Nottingham campus. More: Upperton expands footprint with addition of UK sterile production plant Source: fierce
read moreA squadron of senators is once again putting forward a proposal to boost price transparency in direct-to-consumer pharmaceutical advertising. More: Senators re-up call to include prices in DTC drug ads Source: fierce
read moreDespite finishing strong in 2024, Teva’s cautious approach to the new year appears to have investors spooked. The company’s subdued guidance likely explains the performance of Teva’s stock, which plunged 13% on Wednesday. More: Teva, despite delivering in 2024, startles
read more© 1994 - 2026 B.M. Pharmaceuticals